Related Experiment Video

Updated: Jul 19, 2026

Pre-clinical Model of Cardiac Donation after Circulatory Death
06:26

Pre-clinical Model of Cardiac Donation after Circulatory Death

Published on: August 2, 2019

Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction

Sohail Q Khan1, Dominic Kelly, Paulene Quinn

  • 1Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.

Journal of Cardiac Failure
|October 19, 2006
PubMed

Insights

Cardiotrophin-1 (CT-1) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) can predict adverse outcomes after acute myocardial infarction (AMI). Combining CT-1 and NT-proBNP levels improves prediction of death or heart failure post-AMI.

Area of Science:

  • Cardiology
  • Biomarkers
  • Inflammatory Cytokines

Background:

  • Cardiotrophin-1 (CT-1) is an inflammatory cytokine found in patients post-acute myocardial infarction (AMI).
  • The predictive value of CT-1 for mortality or heart failure after AMI is not well-established.
  • N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a known marker for adverse outcomes in AMI patients.

Purpose of the Study:

  • To investigate the role of CT-1 as a predictor of death or heart failure following AMI.
  • To compare the predictive performance of CT-1 with NT-proBNP.
  • To evaluate the combined predictive value of CT-1 and NT-proBNP.

Main Methods:

  • Studied 291 patients post-AMI.
  • Measured plasma concentrations of CT-1 and NT-proBNP using immunoassays.
  • Followed patients for mortality and heart failure readmissions.
  • Utilized multivariate logistic regression and receiver-operating characteristic (ROC) curve analysis.

Main Results:

  • CT-1 levels were significantly higher in patients who died or were readmitted for heart failure compared to survivors (P = .019).
  • Both CT-1 (OR 1.8, P = .031) and NT-proBNP (OR 2.4, P = .026) independently predicted death or heart failure.
  • The area under the curve (AUC) for CT-1 was 0.62, for NT-proBNP was 0.77, and for the combined model was 0.84.

Conclusions:

  • Combined levels of CT-1 and NT-proBNP provide superior prediction of death or heart failure after AMI compared to either marker alone.
  • CT-1 emerges as a potential independent predictor of adverse outcomes post-AMI.
  • The combination of biomarkers offers enhanced prognostic information for AMI patients.
Abstract

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...